CBD Oil for Sleep and Depression: How CBD Addresses REM Excess, HPA Glucocorticoid Resistance, Inflammatory Cytokine Burden, Morning Early Awakening, and the Depression–Insomnia Bidirectional Cycle

Antidepressant Medications and CBD Oil: Key Interactions

SSRIs (sertraline — CYP2C19; escitalopram/citalopram — CYP2C19/3A4; fluoxetine — CYP2D6/2C9; paroxetine — CYP2D6; fluvoxamine — CYP1A2/2C19): First-line MDD pharmacotherapy. CBD inhibits CYP2C19 (sertraline, escitalopram, citalopram), CYP2D6 (fluoxetine, paroxetine), CYP1A2/2C19 (fluvoxamine), potentially elevating plasma levels of all. Most clinically important: paroxetine (significant CYP2D6 inhibition by CBD → substantial paroxetine elevation, monitor for increased anticholinergic and serotonergic side effects); fluvoxamine (bidirectional CYP complexity — fluvoxamine is itself a CYP1A2/2C19 inhibitor AND a CYP3A4 inhibitor; adding CBD CYP inhibition creates complex bidirectional interaction — requires physician-managed monitoring). Note: SSRIs suppress REM sleep (reducing MDD's pathological REM excess — therapeutically relevant) and often cause initial insomnia from serotonergic activation at treatment start. CBD's 5-HT1A mechanism complements SSRI mechanism through different kinetics. Physician disclosure required before combining with any SSRI.

SNRIs (venlafaxine — CYP2D6/3A4; duloxetine — CYP1A2/2D6): Second-line MDD. CBD's CYP2D6/3A4 inhibition elevates venlafaxine; CYP1A2/2D6 inhibition elevates duloxetine. Both SNRIs suppress REM (beneficial for MDD's REM excess) and can cause initial activation insomnia. Physician disclosure required.

Bupropion (CYP2D6 substrate/inhibitor — activating, dopamine/NE mechanism): Third-line MDD, most likely of all antidepressants to cause or worsen insomnia (NE/dopamine activation, no sedating properties). CBD's CYP2D6 inhibition may significantly elevate bupropion plasma levels — clinically important: bupropion has a dose-dependent seizure risk (elevated plasma levels increase seizure risk). Physician disclosure mandatory before combining CBD with bupropion; do not initiate CBD with bupropion without physician oversight.

Tricyclic antidepressants (amitriptyline, nortriptyline, doxepin — CYP2D6/CYP3A4; QT interval prolongation): Third-line MDD/chronic pain/insomnia (low-dose doxepin is FDA-approved for insomnia). CBD's CYP2D6/3A4 inhibition may significantly elevate TCA plasma levels. Critical concern: TCAs have a narrow therapeutic index and QT-prolonging effects at elevated plasma concentrations — CBD-driven CYP2D6/3A4 elevation of TCAs carries potential cardiac risk. Physician disclosure mandatory; physician should monitor TCA plasma levels and QT interval when initiating CBD in a TCA-treated patient.

Mirtazapine (CYP1A2/2D6/3A4; sedating via H1 antihistamine + 5-HT2 blockade): Second-line MDD, frequently prescribed for depression with insomnia due to its sedating and appetite-stimulating profile. CBD inhibits all three of mirtazapine's metabolic enzymes — significant elevation risk. Additionally, mirtazapine's 5-HT2A/2C blockade may modulate CBD's 5-HT1A effects through serotonin receptor network cross-regulation. Physician disclosure required; complex interaction requiring monitoring for increased sedation (and potential next-morning sedation carryover), weight gain, and other mirtazapine side effects at elevated levels.

MAOIs (phenelzine, tranylcypromine — irreversible; selegiline — MAO-B selective; moclobemide — reversible MAO-A): Fourth-line MDD, rarely prescribed now. CBD's 5-HT1A partial agonism theoretically increases serotonergic tone, and combined with MAOIs' serotonin breakdown inhibition, creates theoretical serotonin syndrome risk (elevated synaptic serotonin from both reduced reuptake and increased presynaptic serotonin output). CBD should be avoided with irreversible MAOIs. Selective MAO-B selegiline at low doses (patch) poses lower serotonin syndrome risk but requires physician guidance. Discuss with prescribing physician before any MAOI/CBD combination.

MDD with Melancholic Features: Severe Early Awakening and Anhedonic Exhaustion

Melancholic MDD — characterized by the most severe anhedonia (complete loss of pleasure), marked diurnal variation with morning being the worst part of the day, early morning awakening, psychomotor changes (retardation or agitation), and marked guilt — has the most severe expression of the sleep architecture abnormalities described above. Early morning awakening in melancholic MDD is typically 3–4 AM (earlier than the 4–5 AM of typical MDD), the morning mood nadir is more pronounced (often the period of highest suicide risk in untreated melancholic MDD), and the inability to return to sleep is more absolute. For melancholic MDD: the extended-release softgel at bedtime is most critical (covering the 3–6 AM early-morning window); physician engagement is highest priority (melancholic MDD warrants professional psychiatric treatment, and CBD is a complementary support, not a substitute for antidepressant pharmacotherapy); the HPA normalization timeline of 8–12 weeks requires patience because the GR resistance of melancholic MDD takes longer to partially normalize than the anxiety-driven HPA hypersecretion of GAD; and SSRI CYP2C19 interaction monitoring is particularly relevant since sertraline and escitalopram are first-line melancholic MDD pharmacotherapy.

Persistent Depressive Disorder (Dysthymia) and High-Functioning Depression: Chronic Low-Grade Insomnia

Persistent depressive disorder (dysthymia) — characterized by chronically depressed mood for 2 or more years, typically less severe than MDD but more sustained — produces a more subtle but chronically maintained version of the same sleep architecture disruption: modest REM latency shortening (75–80 minutes rather than MDD's 65 minutes), less dramatic but consistent N3 deficit, and a persistent pattern of non-restorative sleep that the patient may have lived with for years. High-functioning depression — individuals who maintain career and social functioning while experiencing persistent low mood, reduced energy, hedonic blunting, and poor sleep — often present with early morning awakening (4:30–5:30 AM), poor N3 quality, and the morning worst-mood pattern without the severe anhedonia or functional impairment of clinical MDD. This population is often undertreated (functioning adequately reduces the perceived need for psychiatric engagement) and may be the most likely to self-manage with CBD as a support alongside lifestyle interventions. For persistent/high-functioning depression: CBD's progressive mechanism (building over 8–12 weeks) is well-matched to the chronic, gradual-change character of persistent depressive disorder; daytime 5-HT1A modulation from a midday gummy may address the chronic low-grade energy and mood deficit that maintains the sleep-disrupting HPA activation; and the inflammatory CB2 mechanism is particularly relevant for high-functioning depression with prominent fatigue (inflammatory fatigue in low-grade MDD is common and responds to anti-inflammatory approaches). Professional psychiatric assessment remains appropriate for persistent depressive symptoms regardless of CBD use.

MDD Sleep Protocol: Antidepressant Coordination and Timeline

Physician disclosure before initiating: Required for all antidepressants — particularly mandatory for bupropion (CYP2D6 significant — seizure risk at elevated levels), TCAs (CYP2D6/3A4 — narrow therapeutic index + QT concern), mirtazapine (CYP1A2/2D6/3A4 — complex), and fluvoxamine (bidirectional CYP complexity). For first-line SSRIs (sertraline, escitalopram): physician disclosure before initiating; start CBD at 10 mg and titrate slowly while monitoring for SSRI side effect changes from CYP2C19 inhibition.

Timing for MDD's sleep profile: Sublingual oil 60 minutes before bedtime (standard timing, not the 90-minute anxiety-specific timing). For bupropion-treated patients with activation insomnia: CBD bedtime dose provides a counterweight to bupropion's alerting NE/dopamine mechanism — the adenosine elevation from CBD's FAAH/ENT1 mechanism works directly against bupropion's arousal-maintaining NE activity at bedtime. The combination is CYP2D6-interactive (physician disclosure required) but mechanistically logical for bupropion-treated depression insomnia.

SSRI-lag period: For patients initiating SSRI therapy (first 2–6 weeks when SSRIs cause initial insomnia activation before the autoreceptor desensitization that produces therapeutic benefit): CBD's bedtime dosing during this period supports sleep architecture through adenosine and HPA mechanisms, providing a bridge through the period of most pronounced SSRI-induced sleep disruption. Physician awareness of CBD during SSRI initiation allows monitoring of the combination's combined serotonergic effects.

Start: 10 mg nanoemulsion broad spectrum oil sublingual at bedtime. Titrate 5 mg every 2 weeks. Target: 25–35 mg for MDD-associated insomnia. Add bedtime softgel (10–15 mg) after 2–4 weeks for early-morning awakening coverage. Consider midday gummy (10–15 mg) for daytime inflammatory fatigue and HPA accumulation reduction.

Timeline: Sleep-onset latency improvements: 4–6 weeks. N3 quality improvement (reduced morning exhaustion despite sleep): 6–8 weeks. Early morning awakening frequency reduction: 8–12 weeks (this is the last metric to improve, reflecting the HPA CAR normalization timeline). For patients on SSRIs concurrently: the SSRI's own sleep-normalizing effects (REM suppression, mood stabilization) may interact with and enhance CBD's sleep-architecture benefits over the 6–12 week period, potentially making the combined approach more effective than either alone for the full MDD sleep profile.

Does CBD oil help with sleep when depression is the cause?

CBD oil addresses depression-driven insomnia through mechanisms that target MDD's specific neurobiological sleep disruption rather than through sedation. The 5-HT1A partial agonist mechanism supports the serotonergic REM-off system (the same aminergic system whose reduced function in MDD produces the shortened REM latency and REM excess that characterizes depressed sleep); the HPA normalization mechanism reduces the cortisol hypersecretion that suppresses N3 sleep and generates early morning awakening; the CB2/PPARγ anti-inflammatory mechanism reduces the cytokine burden that promotes pathological REM in inflammatory MDD subtypes; and adenosine elevation through FAAH/ENT1 inhibition promotes N3 slow-wave sleep that MDD characteristically depletes. The Shannon et al. (2019) large case series included patients with anxiety and insomnia (many of whom had comorbid depressive symptoms), showing that 66.7% of patients experienced improved sleep scores within the first month, sustained over three months — consistent with the progressive timeline of CBD's HPA and 5-HT1A mechanisms for depression-related sleep improvement. CBD is not an antidepressant — it does not replace professional psychiatric treatment for MDD — but for the specific sleep-architecture manifestation of depression (REM excess, N3 deficit, early morning awakening), CBD's mechanisms engage the same neurobiological systems that MDD disrupts.

Can CBD oil be used with antidepressants for sleep?

CBD oil can be used alongside antidepressants for sleep in many cases, but physician disclosure before initiating is required because CBD inhibits the CYP enzymes that metabolize most antidepressants. The interaction complexity varies by medication: SSRIs (sertraline, escitalopram — CYP2C19; fluoxetine, paroxetine — CYP2D6; fluvoxamine — CYP1A2/2C19): potential SSRI plasma elevation requiring monitoring for SSRI side effect changes — physician disclosure allows dose monitoring. SNRIs (venlafaxine, duloxetine): CYP2D6/3A4 interaction requires monitoring. Bupropion: CYP2D6 significant elevation risk — mandatory physician disclosure given bupropion's dose-dependent seizure risk at elevated levels. TCAs (amitriptyline, nortriptyline, doxepin): CYP2D6/3A4 interaction + QT prolongation concern at elevated TCA levels — mandatory physician disclosure and monitoring. Mirtazapine: CYP1A2/2D6/3A4 complex interaction with significant elevation risk — physician management required. For SSRI-treated MDD patients initiating CBD during SSRI therapy: the mechanistic relationship is complementary (CBD's 5-HT1A partial agonism at DRN autoreceptors and SSRI-induced 5-HT1A desensitization engage the same system through different pharmacological approaches), but the CYP2C19/2D6 interaction means SSRI plasma levels may increase — physician-supervised combination at lower initial CBD doses with monitoring is the appropriate approach. Never adjust antidepressant doses without physician guidance when adding CBD.

Does CBD oil help with early morning waking from depression?

Early morning awakening — waking spontaneously at 3–5 AM with inability to return to sleep and worst mood of the day — is the most diagnostically characteristic and most CBD-relevant sleep symptom in MDD. The mechanism driving early morning awakening in depression is the exaggerated and early-timed cortisol awakening response (CAR): MDD's HPA hypersecretion produces a cortisol pulse at 2–4 AM (rather than the normal 5–6 AM) that activates the amygdala, triggers the ruminative and hopeless morning cognition, and prevents return to sleep at the circadian monoaminergic nadir when the depressed brain has its lowest serotonin and NE. CBD oil's HPA normalization mechanism through CRF attenuation is the most directly targeted mechanism for this specific symptom: consistent CBD use over 8–12 weeks reduces the CRF drive that produces the exaggerated CAR, potentially delaying and attenuating the early-morning cortisol pulse that terminates sleep prematurely. The bedtime softgel (extended-release nanoemulsion, 6–8 hour duration) provides CBD plasma coverage through the 3–6 AM early-morning window that the sublingual oil's declining levels may not fully reach. Realistically: early morning awakening is the last MDD sleep metric to improve with CBD — it typically begins improving after 8–10 weeks of consistent dosing, well after sleep-onset improvements. Patience with this specific symptom's timeline is important; it reflects the sustained HPA reprogramming that CRF normalization requires, rather than a lack of CBD effect.

Is CBD oil an antidepressant?

CBD oil is not an antidepressant and does not treat MDD as a therapeutic agent. This is an important distinction: CBD's 5-HT1A partial agonism engages the serotonergic system that antidepressants target, and CBD has demonstrated anxiolytic effects in human studies (with anxiety and depression often comorbid, CBD's anxiety reduction may reduce depressive symptom burden in anxiety-comorbid MDD) — but CBD has not been demonstrated in clinical trials to reduce the core depressive symptoms (persistent low mood, anhedonia, hopelessness) in major depressive disorder at the level that constitutes antidepressant efficacy. CBD may address the inflammatory dimension of depression (CB2/PPARγ anti-inflammatory) and the sleep-architecture manifestation of depression (5-HT1A REM-off support, adenosine N3 promotion, HPA CAR normalization) — reducing the sleep-related perpetuating factors of depression and potentially reducing the inflammatory burden in cytokine-driven MDD. But these are not the same as treating MDD as an antidepressant does. The appropriate framing: CBD is a mechanistically relevant complementary support for the sleep and inflammatory dimensions of MDD, to be used alongside professional psychiatric treatment (CBT, antidepressant pharmacotherapy, or both) — not as a substitute for it. Individuals with MDD symptoms (persistent low mood, anhedonia, hopelessness, functional impairment) should seek professional psychiatric or psychological evaluation; CBD use while pursuing that evaluation and treatment is reasonable, but CBD should not delay or replace professional care for clinical depression.

How does CBD oil for sleep in depression differ from CBD oil for sleep in anxiety?

CBD oil's sleep mechanism in depression and anxiety share the same pharmacological mechanisms (5-HT1A, HPA normalization, adenosine) but target different neurobiological expressions of those shared mechanisms. In anxiety-driven insomnia, the primary problem is anxiety-generated hyperarousal preventing sleep onset — the amygdala hyperreactivity, HPA cortisol elevation from CRF hypersecretion (threat-driven rather than GR-resistance-driven), and the cognitive arousal of worry preventing the cortical deactivation that sleep requires. CBD's 5-HT1A desensitizes the amygdala and HPA cortisol begins to reduce — and once the anxiety hyperarousal is removed, the brain's natural sleep mechanisms can initiate sleep. In depression-driven insomnia, the primary problems are structural sleep architecture abnormalities — shortened REM latency/REM excess from monoaminergic disinhibition of the cholinergic REM-on system, N3 deficit from cortisol GH suppression, and early morning awakening from the exaggerated CAR — rather than sleep-onset hyperarousal. CBD's 5-HT1A supports the aminergic REM-off system (not primarily calming anxiety arousal but supporting the monoaminergic system whose failure produces REM excess); adenosine directly supports N3 slow-wave sleep that MDD depletes; and HPA normalization addresses the exaggerated early morning CAR that terminates sleep prematurely. Practical timing difference: the 60–90 minute pre-sleep timing used for anxiety-driven insomnia (positioned for peak CBD during the pre-sleep anxiety peak) vs. the standard 60-minute pre-sleep timing for MDD (the sleep architecture problem is during sleep, not preventing its onset). Early morning awakening coverage with a bedtime softgel is more critical in MDD than in anxiety-driven insomnia.

Does CBD oil help with depression fatigue and daytime exhaustion?

CBD oil may address the fatigue dimension of depression through two distinct mechanisms that are relevant for different fatigue subtypes. For cytokine-driven fatigue (the sickness-behavior fatigue of inflammatory MDD — characterized by profound exhaustion, social withdrawal, hypersomnia, and anhedonia that does not respond to rest): CBD's CB2/PPARγ anti-inflammatory mechanism reduces the IL-1β, IL-6, and TNF-α cytokine burden that drives this sickness-behavior fatigue at the molecular level. This mechanism takes 4–8 weeks to produce meaningful cytokine reduction, and the timeline for inflammatory fatigue improvement in CBD responders aligns with the 4–8 week CB2/PPARγ timeline. For HPA-driven fatigue (the cortisol-dysregulation fatigue of HPA-hyperactive MDD — characterized by morning worst, improving through the day; difficulty initiating activity despite cognitive willingness; fatigue paradoxically worse after low effort): CBD's HPA normalization through CRF attenuation may partially normalize the blunted morning CAR that produces the morning energy nadir. In both cases, CBD's sleep architecture restoration — particularly N3 promotion through adenosine — produces more restorative sleep quality over time, reducing the sleep-deprivation component of depressive fatigue (the cumulative N3 deficit that leaves MDD patients structurally under-rested regardless of sleep duration). The honest assessment: CBD's fatigue benefit in MDD is a secondary consequence of anti-inflammatory and sleep-restorative mechanisms, not a direct stimulant effect. Do not expect immediate energy improvement; expect gradual improvement in the quality of rest and reduction in inflammatory fatigue burden over 6–10 weeks of consistent use.

How much CBD oil should I take for depression and sleep?

CBD oil dosing for depression-driven insomnia follows the standard protocol with modifications for antidepressant interaction and early-morning awakening coverage. Start: 10 mg nanoemulsion broad spectrum oil sublingual, 60 minutes before bedtime. Titrate: 5 mg every 2 weeks. Target range: 25–35 mg for MDD-associated insomnia. For patients on SSRIs or SNRIs: titrate more slowly (5 mg every 3 weeks) due to CYP enzyme interactions — physician disclosure and slower titration allows monitoring for SSRI/SNRI plasma level changes. Add bedtime softgel: after 2–4 weeks of establishing the sublingual oil dose, add 10–15 mg bedtime softgel for early-morning awakening coverage. Optional midday gummy: 10–15 mg midday for inflammatory fatigue and daytime HPA accumulation. Total daily dose (full protocol): 25–35 mg bedtime oil + 10–15 mg bedtime softgel + 10–15 mg optional midday gummy = 45–65 mg total daily. For higher doses (above 35 mg at bedtime), physician disclosure becomes more important due to increasing SSRI/SNRI CYP enzyme interaction magnitude at higher CBD plasma levels. Timeline: sleep-onset improvement (if present) at 4–6 weeks; N3 quality improvement at 6–8 weeks; early morning awakening reduction at 8–12 weeks. Complete evaluation at 12 weeks for the full MDD-sleep benefit. Do not evaluate at 4 weeks and conclude non-response — early morning awakening improvement requires the full 8–12 week HPA normalization timeline.

Does CBD oil affect REM sleep in depression?

CBD oil's effect on REM sleep in depression operates through the serotonergic mechanism that underlies MDD's pathological REM excess, rather than through direct REM suppression. In untreated MDD, REM begins too early (shortened REM latency), lasts too long (enlarged first REM episode), and is too dense (elevated eye movement activity). This REM excess arises from reduced serotonergic and noradrenergic activity in the brainstem REM-off system — the aminergic inhibition of cholinergic REM-on neurons is reduced in MDD, allowing premature REM breakthrough. CBD's 5-HT1A partial agonism at dorsal raphe serotonergic neurons modulates the serotonergic output of the raphe to the brainstem REM-off system — potentially supporting the aminergic REM-off function that MDD compromises. This is a modulatory mechanism (partial agonism, not full serotonin reuptake blockade) and its REM-normalizing effect is likely more modest than SSRI-driven REM suppression. SSRIs consistently and markedly suppress REM (a primary pharmacological effect); CBD's effect would be a more modest modulation of REM latency and REM proportion rather than pronounced suppression. For MDD patients on SSRIs (which suppress REM) using CBD concurrently: the combined effect on REM architecture would be primarily SSRI-driven, with CBD contributing through 5-HT1A modulation and N3-promoting adenosine. Importantly: CBD at therapeutic doses does not suppress REM in healthy non-depressed individuals; the 5-HT1A mechanism normalizes dysregulated REM rather than globally suppressing it — an important distinction from benzodiazepines and Z-drugs, which suppress both REM and N3 non-selectively.

Is full spectrum or broad spectrum CBD oil better for depression and sleep?

Broad spectrum CBD oil (THC-free) is recommended for depression-driven insomnia rather than full spectrum. The rationale: THC has a well-characterized biphasic anxiety effect (anxiolytic at low doses, anxiety-amplifying at moderate-to-high doses through CB1-mediated amygdala sensitization). Depression has a 60–70% comorbidity rate with anxiety disorders — the majority of MDD patients also have clinically significant anxiety. In an anxiety-comorbid MDD patient, THC's anxiety-amplifying effect at moderate doses could worsen the anxiety that is both comorbid with and perpetuating the depression. Additionally, THC's CB1 agonism at REM-regulatory brainstem circuits may interact with MDD's already-disrupted REM architecture in unpredictable ways. Broad spectrum CBD eliminates these risks entirely while preserving the CBD, CBG, and minor cannabinoids that may contribute to the entourage effect (the hypothesis that minor cannabinoids and terpenes enhance CBD's primary mechanisms). For the approximately 30–40% of MDD patients without significant anxiety comorbidity: the THC risk is lower, but the absence of a clear advantage for full spectrum in MDD-specific sleep mechanisms (THC's primary contribution is CB1 pain and mild sedation — less relevant for MDD's monoaminergic and HPA mechanisms) makes broad spectrum the appropriate default. Full spectrum is more appropriate for MDD with comorbid chronic pain (where CB1 pain contribution adds clinical value) — but for pure MDD-associated sleep disruption, broad spectrum with its cleaner 5-HT1A, HPA, and CB2 profile is better matched to the mechanisms relevant to depression-driven insomnia.

What is the best CBD oil product for sleep in depression?

The optimal CBD oil product selection for depression-driven insomnia centers on three criteria: broad spectrum (THC-free, for anxiety comorbidity protection and cleaner mechanism profile for MDD), nanoemulsion format (for consistent bioavailability essential to the progressive HPA and 5-HT1A mechanisms), and dual delivery (sublingual onset for bedtime 5-HT1A/adenosine support + extended-release coverage for early-morning awakening). The Nano CBD Broad Spectrum Oil (sublingual, 60 minutes before bedtime) is the essential foundation — fastest onset for the bedtime 5-HT1A and adenosine mechanisms, consistently high bioavailability for progressive HPA normalization. The Nano CBD Water-Soluble Broad Spectrum Softgels (bedtime, alongside the oil) is the second-priority addition for MDD — extended 6–8 hour coverage through the 3–6 AM early-morning awakening window that is MDD's most characteristic and most disabling sleep disruption. For inflammatory-fatigue-prominent MDD: add the Nano CBD Infused Vegan Broad Spectrum Gummies at midday for CB2 anti-inflammatory coverage during the daytime peak of cytokine production. Third-party tested, verified THC-free products are especially important for MDD patients — the anxiety-amplifying effects of undetected THC contamination could worsen the anxiety comorbidity that affects the majority of MDD patients.

Medical Disclaimer

This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent major depressive disorder, persistent depressive disorder, or any other mood disorder or medical condition. CBD oil is not an antidepressant and is not a substitute for professional psychiatric or psychological treatment for depression. Major depressive disorder is a serious medical condition that requires professional evaluation and may require physician-prescribed pharmacotherapy, cognitive behavioral therapy, or other professional interventions. CBD oil does not replace these treatments and does not constitute professional medical or psychiatric care. Individuals experiencing depression, persistent low mood, loss of interest, hopelessness, or thoughts of self-harm should seek professional psychiatric or psychological evaluation immediately. If you are experiencing thoughts of suicide or self-harm, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988. Individuals taking antidepressant medications (SSRIs, SNRIs, TCAs, bupropion, mirtazapine, MAOIs) must disclose CBD use to their prescribing physician before initiating, due to CYP enzyme interactions that may alter plasma levels of these medications. The statements in this article have not been evaluated by the Food and Drug Administration. Individual responses to CBD vary. This article does not constitute medical or psychiatric advice — consult your physician or mental health professional before making changes to your depression or sleep treatment regimen.